Annabel Simons

Real-world screening for metabolic dysfunction-associated steatotic liver disease among adults with type 2 diabetes.

The impact of population-level MASLD screening is limited by implementation barriers and future efforts should focus on direct-to-patient outreach and methods to identify patients without competing risks who are most likely to benefit from MASLD diagnosis and specific treatment.